Shots:

• Dragonfly to receive upfront- milestones and royalties on licensed therapies. AbbVie to get an exclusive option to license global intellectual property rights to develop and commercialize therapies developed during the collaboration
• Dragonfly will utilize its TriNKET platform for developing therapies targeting multiple autoimmune and oncology indications
• Dragonfly’s novel TriNKET technology acts by enhancing immunotherapy utilizing NK cells- thus harnessing the body's innate immune system to bring breakthrough cancer therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: AbbVie